TPST News and Press, Tempest Therapeutics Inc. From 04/04/24

TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancers Based on subsequent positive randomized data, Company preparing to move TPST-1120 into pivotal Phase 3 trial in HCC ...

A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...

2024-03-19 16:37:42 ET More on Tempest Therapeutics Seeking Alpha’s Quant Rating on Tempest Therapeutics Historical earnings data for Tempest Therapeutics Financial information for Tempest Therapeutics Read the full article on Seeking Alpha For...

Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of care Reported new biomarker data in two important subpopulations, PD-L1 negative and b-catenin mutant patients, consistent with Mo...

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors’ and officers’ possible violations of state laws. If you own Tempest Therapeutics stock, would like to learn mo...

BRISBANE, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced a poster presentation at the Society for Immunotherapy ...

BRISBANE, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that collaborators at the Beth Israel Deaconess Medical...

BRISBANE, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced that Stephen Brady, president and chief executive office...

BRISBANE, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class 1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced that the Compensation Committee of the Company&#...

2023-11-22 11:16:40 ET Penny stocks refer to shares of small or micro-cap companies that trade for less than $5 per share. What cheap stocks lack in size and stability, they can potentially make up for in rapid price changes and explosive short-term gains. For risk-tolerant investors, a...